CG
Therapeutic Areas
Tectonic Therapeutic Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TX45 | Heart Failure with Preserved Ejection Fraction (HFpEF) and other fibrotic diseases | Phase 1 |
Leadership Team at Tectonic Therapeutic
AR
Alise Reicin, M.D.
President and Chief Executive Officer
AA
Andrew A. F. Hack, M.D., Ph.D.
Chief Financial Officer and Head of Business Development
ST
Samantha Truex, J.D.
Chair of the Board of Directors
PG
Peter G. Schultz, Ph.D.
Co-founder and Board Member
AK
Andrew Kruse, Ph.D.
Co-founder and Scientific Advisory Board Chair
EC
Erin C. Bush, Ph.D.
Senior Vice President, Head of Research
JS
Joseph S. Krueger, Ph.D.
Senior Vice President, Head of Development
R(
Robert (Bob) R. Ruffolo, Ph.D.
Board Member
K(
Katherine (Kate) Bingham, D.Phil.
Board Member
SL
Seth L. Harrison, M.D.
Board Member